In Connecticut, Compound Laws tracks 19 compounds: 6 legal to sell at retail, 1 restricted, 0 in a gray area, 7 illegal, and 5 whose status varies by product form. Verified through October 22, 2026.
b602a77314ad240e(c) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (44) 7-hydroxymitragynine; (45) Bromazolam; (46) Flubromazolam; (47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts; (48) Nitazenes, including, but not limited to, isotonitazene; (49) Tianeptine; and (50) Phenibut. (Effective July 23, 1987; Amended ... Amended February 10, 2023; Amended April 2, 2026) [Full (a)-(g) section available at official URL; subsection (c) is the operative kratom-scheduling instrument, items (44) and (47) captured verbatim.]
b1eb51cbe6059976**Scheduling gap — § 21a-243-7(c):** the only tryptamines listed are alpha-ethyltryptamine, 5-MeO-DiPT, bufotenine/mappine, DET, DMT, … psilocybin, psilocyn; each is named individually and the sweep reaches only "their salts, isomers and salts of isomers." No "4-hydroxytryptamine" class, no general tryptamine catch-all. 4-HO-MET is not named and (as a homolog, not isomer) is not captured. — Conn. Agencies Regs. § 21a-243-7(c) (amended, Tracking No. PR2025-018, posted 9/18/2025), official CT eRegulations: https://eregulations.ct.gov/eRegsPortal/Search/RCSADisplay/21a-243-7 **Definitional category, but NOT an independent schedule — Conn. Gen. Stat. § 21a-240(23):** "'Hallucinogenic substances' … Exemplary of such drugs are mescaline, peyote, psilocyn and d-lysergic acid diethylamide, which are controlled substances under this chapter unless modified." A substance is a "controlled substance" only if listed in Schedules I–V of the regulations (§ 21a-240(9)) — so this definition does **not** independently schedule 4-HO-MET. — Conn. Gen. Stat. § 21a-240(23), (9); via labeled Justia mirror (2024), full section read: https://law.justia.com/codes/connecticut/title-21a/chapter-420b/section-21a-240/
d90038b9489d866eConn. Gen. Stat. 21a-240(62) (as amended by P.A. 24-76): 'Synthetic cannabinoid' (A) means any substance converted, by a chemical process, to create a cannabinoid or cannabinoid-like substance that (i) has structural features which allow interaction with at least one of the known cannabinoid-specific receptors, or (ii) has any physiological or psychotropic response on at least one cannabinoid-specific receptor, (B) includes, but is not limited to, hexahydrocannabinol (HHC and HXC) and hydrox4phc (PHC), and (C) does not include any manufactured cannabinoid. Conn. Gen. Stat. 21a-420k(v): No manufacturer hemp product offered for sale in this state, or to a consumer in this state, shall contain any synthetic cannabinoid, as defined in section 21a-240, as amended by this act. P.A. 24-115 Sec. amending Conn. Gen. Stat. 21a-243(j): Notwithstanding the provisions of subsection (c) of this section, the Commissioner of Consumer Protection shall designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances in schedule I of the controlled substances scheduling regulations: (1) Mephedrone (4-methylmethcathinone); (2) Synthetic cannabinoids; and (3) MDPV (3,4-methyenedioxypyrovalerone). P.A. 24-115 Sec. 6(f): Synthetic cannabinoids, as defined in section 21a-240, as amended by this act, are prohibited in cannabis, and no synthetic cannabinoid may be sold at any cannabis establishment.
3292f002f3ff0230(63) "High-THC hemp product" (A) prior to October 1, 2024, means a manufacturer hemp product, as defined in section 22-61l, that has, or is advertised, labeled or offered for sale as having, total THC that exceeds: (i) For a hemp edible, hemp topical or hemp transdermal patch (I) one milligram on a per-serving basis, or (II) five milligrams on a per-container basis; (ii) for a hemp tincture, including, but not limited to, oil intended for ingestion by swallowing, buccal administration or sublingual absorption (I) one milligram on a per-serving basis, or (II) twenty-five milligrams on a per-container basis; (iii) for a hemp concentrate or extract, including, but not limited to, a vape oil, wax or shatter, twenty-five milligrams on a per-container basis; or (iv) for a manufacturer hemp product not described in subparagraph (A)(i), (A)(ii) or (A)(iii) of this subdivision, (I) one milligram on a per-serving basis, (II) five milligrams on a per-container basis, or (III) three-tenths per cent on a dry-weight basis for cannabis flower or cannabis trim, (B) on and after October 1, 2024, means a manufacturer hemp product, as defined in section 22-61l that has, or is advertised, labeled or offered for sale as having, total THC that exceeds (i) one milligram per serving with up to five milligrams per-container, or (ii) three-tenths per cent on a dry-weight basis for cannabis flower or cannabis trim, and (C) does not include an infused beverage, as defined in section 26 of public act 24-76. As used in this subdivision, "container" means an object that is offered, intended for sale or sold to a consumer and directly contains a high-THC hemp product, and does not include an object or packaging that indirectly contains, or contains in bulk for transportation purposes, a high-THC hemp product.
7e49f051710513dcThe following words and phrases, as used in this chapter, shall have the following meanings, unless the context otherwise requires: (7) "Cannabis-type substances" include all parts of any plant, or species of the genus cannabis or any infra specific taxon thereof whether growing or not; the resin extracted from any part of such a plant; and every compound, manufacture, salt, derivative, mixture or preparation of such plant, or its resin; but shall not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil or cake, the seed of such plant, or hemp, as defined in 7 USC 1639o, as amended from time to time. Included are cannabinon, cannabinol, cannabidiol and chemical compounds which are similar to cannabinon, cannabinol or cannabidiol in chemical structure or which are similar thereto in physiological effect, and which show a like potential for abuse, which are controlled substances under this chapter unless derived from hemp, as defined in section 22-61l. (28) "Manufacture" means the production, preparation, cultivation, growing, propagation, compounding, conversion or processing of a controlled substance, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a controlled substance by an individual for the individual's own use or the preparation, compounding, packaging or labeling of a controlled substance: (A) By a practitioner as an incident to the practitioner administering or dispensing of a controlled substance in the course of such practitioner's professional practice; or (B) by a practitioner, or by the practitioner's authorized agent under such practitioner's supervision, for the purpose of, or as an incident to, research, teaching or chemical analysis and not for sale. (29) "Marijuana" means all parts of any plant, or species of the genus cannabis or any infra specific taxon thereof, whether growing or not; the resin extracted from any part of the plant; every compound, manufacture, salt, derivative, mixture or preparation of such plant, or its resin; any high-THC hemp product; manufactured cannabinoids; or cannabinon, cannabinol or cannabidiol and chemical compounds which are similar to cannabinon, cannabinol or cannabidiol in chemical structure or which are similar thereto in physiological effect, which are controlled substances under this chapter, except cannabidiol derived from hemp, as defined in section 22-61l, that is not a high-THC hemp product. "Marijuana" does not include: (A) The mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture or preparation of such mature stalks, except the resin extracted from such mature stalks or fiber, oil or cake; (B) the seed of such plant; (C) hemp, as defined in section 22-61l, (i) with a total THC concentration of not more than three-tenths per cent on a dry-weight basis, and (ii) that is not a high-THC hemp product; (D) any substance approved by the federal Food and Drug Administration or successor agency as a drug and reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency which is included in the same schedule designated by the federal Drug Enforcement Administration or successor agency; or (E) infused beverages, as defined in section 26 of public act 24-76. (59) "THC" means tetrahydrocannabinol, including, but not limited to, delta-7, delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol and delta-10-tetrahydrocannabinol, and any material, compound, mixture or preparation which contain their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation, regardless of the source, except: (A) Dronabinol substituted in sesame oil and encapsulated in a soft gelatin capsule in a federal Food and Drug Administration or successor agency approved product; or (B) any tetrahydrocannabinol product that has been approved by the federal Food and Drug Administration or successor agency to have a medical use and reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency. (60) "Total THC" means the sum of the percentage by weight of tetrahydrocannabinolic acid, multiplied by eight hundred seventy-seven-thousandths, plus the percentage of weight of THC. (61) "Manufactured cannabinoid" means cannabinoids created by directly converting one cannabinoid to a different cannabinoid through: (A) Application of light or heat; (B) decarboxylation of naturally occurring acidic forms of cannabinoids; or (C) an alternate extraction or conversion process approved by the Department of Consumer Protection and published on the department's Internet web site. (62) "Synthetic cannabinoid" (A) means any substance converted, by a chemical process, to create a cannabinoid or cannabinoid-like substance that (i) has structural features which allow interaction with at least one of the known cannabinoid-specific receptors, or (ii) has any physiological or psychotropic response on at least one cannabinoid-specific receptor, (B) includes, but is not limited to, hexahydrocannabinol (HHC and HXC) and hydrox4phc (PHC), and (C) does not include any manufactured cannabinoid.
5f969cee8dd2ef28(a) As used in this section: (1) "Cannabis establishment" has the same meaning as provided in section 21a-420; (2) "Consumer" has the same meaning as provided in section 21a-420; (3) "Container" (A) means an object that is offered, intended for sale or sold to a consumer and directly contains (i) a manufacturer hemp product, or (ii) a moderate-THC hemp product, and (B) does not include an object or packaging that indirectly contains, or contains in bulk for transportation purposes, (i) a manufacturer hemp product, or (ii) a moderate-THC hemp product; (4) "Manufacturer" has the same meaning as provided in section 22-61l; (5) "Manufacturer hemp product" has the same meaning as provided in section 22-61l; (6) "Moderate-THC hemp product" (A) means a manufacturer hemp product that has total THC, as defined in section 21a-240, of not less than one-half of one milligram, and not more than five milligrams, on a per-container basis, and (B) does not include (i) an infused beverage, as defined in section 21a-425, or (ii) a legacy infused beverage, as defined in section 21a-425; and (7) "Moderate-THC hemp product vendor" means a person that (A) holds a certificate of registration issued by the Commissioner of Consumer Protection pursuant to this section, and (B) is not a cannabis establishment. (b) Beginning on January 1, 2025, no person shall sell or offer to sell, at retail, any moderate-THC hemp product in the state to consumers unless such person is a cannabis establishment or holds a certificate of registration issued by the Commissioner of Consumer Protection pursuant to this section. The provisions of this section shall not apply to the wholesale or commercial distribution of moderate-THC hemp products for resale. (e) No cannabis establishment or moderate-THC hemp product vendor, or agent or employee of a cannabis establishment or moderate-THC hemp product vendor, shall sell a moderate-THC hemp product to any individual who is younger than twenty-one years of age. Prior to selling any moderate-THC hemp product to an individual, the cannabis establishment, moderate-THC hemp product vendor, agent or employee shall first verify the individual's age with a valid government-issued driver's license or identity card to establish that such individual is twenty-one years of age or older. (f) No person shall sell any moderate-THC hemp product intended for human ingestion in packaging that includes more than two containers. (i) Each moderate-THC hemp product container shall prominently display a symbol, in a size of not less than one-half inch by one-half inch and in a format approved by the Commissioner of Consumer Protection, that indicates that such moderate-THC hemp product is not legal or safe for individuals younger than twenty-one years of age. (P.A. 24-76, S. 31; 24-95, S. 4.)
d9f46f5d41aa02ef(a) For the purpose of this section and section 22-61m, the following terms have the same meaning as provided in 7 CFR 990.1, as amended from time to time: "Acceptable hemp THC level", "Agricultural marketing service", "Audit", "Cannabis", "Conviction", "Corrective action plan", "Culpable mental state greater than negligence", "Decarboxylated", "Decarboxylation", "Disposal", "Dry weight basis", "Gas chromatography", "Geospatial location", "Handle", "Liquid chromatography", "Immature plants", "Information sharing system", "Measurement of uncertainty", "Negligence", "Phytocannabinoid", "Postdecarboxylation", "Remediation", "Reverse distributor" and "Total THC". In addition, for the purpose of this section and section 22-61m: (7) "Hemp" has the same meaning as provided in the federal act; (8) "Hemp products" means all manufacturer hemp products and producer hemp products; (13) "Manufacture" means the conversion of the hemp plant into a by-product by means of adding heat, solvents or any method of extraction that modifies the original composition of the plant for the purpose of creating a manufacturer hemp product for commercial or research purposes; (15) "Marijuana" has the same meaning as provided in section 21a-240; (24) "THC" means delta-9-tetrahydrocannabinol; (30) "Manufacturer hemp product" (A) means a commodity manufactured from the hemp plant, for commercial or research purposes, that is intended for human ingestion, inhalation, absorption or other internal consumption, that contains a THC concentration of not more than 0.3 per cent on a dry weight basis or per volume or weight of such manufacturer hemp product, and (B) does not include an infused beverage, as defined in section 26 of public act 24-76; (32) "Producer hemp product" means any of the following produced in this state: Raw hemp product, fiber-based hemp product or animal hemp food product, and each of which contains a THC concentration of not more than 0.3 per cent on a dry weight basis or per volume or weight of such producer hemp product; (f) Any person who sells hemp products shall not be required to be licensed provided such person only engages in: (1) The retail or wholesale sale of hemp or hemp products in which no further producing or manufacturing of the hemp products occurs and the hemp products are acquired from a person authorized under the laws of this state or another state, territory or possession of the United States or another sovereign entity to possess and sell such hemp products; (2) the acquisition of hemp or hemp products for the sole purpose of product distribution for resale; or (3) the retail sale of hemp products that are otherwise authorized under federal or state law.
e0b040f478bf1fae[PA 25-101] Sec. 20, 21a-426(a)(4): ["Hemp flower" means] "the flower, including, but not limited to, any abnormal or immature flower, of hemp" [and excludes leaves and stem]. (a)(7) [Moderate-THC hemp product: total THC] "not less than one-half of one milligram, and not more than five milligrams" [per container]. Sec. 1(b)(1) [Persons who are not moderate-THC vendors or cannabis establishments may sell hemp flower only in person or by delivery; in-person flower must be kept] "behind a sales counter that is inaccessible to consumers" [or in a locked container]. (b)(2) [Age verified] "prior to purchase and upon delivery, with a valid government-issued driver's license or identity card." [OLR summary: sellers may not sell to anyone] "younger than age 21." [Effective October 1, 2025.] [Bracketed spans summarized.]
483048084506f8ecSec. 21a-243-7. Controlled substances in schedule I The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in schedule I: (a) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetylalpha-methylfentanyl; (2) Acetylmethadol; (3) Allylprodine; (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM); (5) Alphameprodine; (6) Alphamethadol; (7) Alpha-methylfentanyl; (8) Alphamethylthiofentanyl; (9) Benzethidine; (10) Betacetylmethadol; (11) Beta-hydroxy-fentanyl; (12) Beta-hydroxy-3-methylfentanyl; (13) Betameprodine; (14) Betamethadol; (15) Betaprodine; (16) Clonitazene; (17) Dextromoramide; (18) Diampromide; (19) Diethylthiambutene; (20) Difenoxin; (21) Dimenoxadol; Regulation - Page 1 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 (22) Dimepheptanol; (23) Dimethylthiambutene; (24) Dioxaphetyl Butyrate; (25) Dipipanone; (26) Ethylmethylthiambutene; (27) Etonitazene; (28) Etoxeridine; (29) Furethidine; (30) Hydroxypethidine; (31) Ketobemidone; (32) Levomoramide; (33) Levophenacylmorphan; (34) 3-methylfentanyl; (35) 3-methylthiofentanyl; (36) Morpheridine; (37) Noracymethadol; (38) Norlevorphanol; (39) Normethadone; (40) Norpipanone; (41) Para-fluorofentanyl; (42) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (43) Phenadoxone; (44) Phenampromide; (45) Phenomorphan; (46) Phenoperidine; (47) Piritramide; (48) Proheptazine; (49) Properidine; (50) Propiram; (51) Racemoramide; (52) Thiofentanyl; (53) Tilidine; (54) Trimeperidine. (b) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Acetorphine; Regulation - Page 2 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine, except hydrochloride salts; (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Morphine methylbromide; (16) Morphine methylsulfonate; (17) Morphine-N-oxide; (18) Myrophine; (19) Nicocodeine; (20) Nicomorphine; (21) Normorphine; (22) Pholcodine; (23) Thebacon. (c) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine; (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA; (3) 2,5-dimethoxyamphetamine; or 2,5-DMA; (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET; (5) 3,4-M ethylenedioxy-N-ethylamphetamine; (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP; (7) 3,4-methylenedioxymethamphetamine; or MDMA; (8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7); (9) 4-methoxyamphetamine; or PMA; (10) 5-methoxy-3,4-methylenedioxy-amphetamine; (11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt); (12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP Regulation - Page 3 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 (13) 3,4-methylenedioxy amphetamine; or MDA; (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha- methyl- 3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA; (15) 3,4,5-trimethoxy amphetamine; (16) benzylpiperazine or BZP; (17) Bufotenine or Mappine; (18) Alphaethyltryptamine; (19) Diethyltryptamine or DET; (20) Dimethyltryptamine or DMT; (21) Ibogaine; (22) Lysergic acid diethylamide; (23) MDVP (3,4-methylenedioxypyrovalerone); (24) 3,4-methylenedioxy-N-methycathione (methylone) (25) Mephedrone (4-methylmethcathinone); (26) Mescaline; (27) Parahexyl or Synhexyl; (28) Peyote, meaning all parts of the plants; (29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP; (30) N-ethyl-3-piperidyl benzilate; (31) N-methyl-3-piperidyl benzilate; (32) Psilocybin; (33) Psilocyn; (34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product; (35) Salvia divinorum; (36) Salvinorin A; (37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE; (38) 4-Bromo-2,5-dimethoxyphenethylamine; (39) Pyrrolidine analog of phencyclidine, PCP or PHP; (40) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; (41) Thiophene analog of phencyclidine, TPCP or TCP; (42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; (43) Trifluoromethylphenylpiperazine or TFMPP. (44) 7-hydroxymitragynine; (45) Bromazolam; (46) Flubromazolam; (47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts; (48) Nitazenes, including, but not limited to, isotonitazene; (49) Tianeptine; and Regulation - Page 4 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 (50) Phenibut. (d) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the Food, Drug and Cosmetic Act; (2) Gamma-butyrolactone; (3) Mecloqualone; (4) Methaqualone; or (5) Zolazepam. (e) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Aminorex; (2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine); (3) 4-Methylaminorex; (4) Cathinone; (5) Fenethylline; (6) Methcathinone; (7) N-ethylamphetamine; (8) N,N-Dimethylamphetamine. (f) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to: (1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018); (2) 1-butyl-3-(1-naphthoyl)indole (JWH-073); (3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); (4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); (5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabi-cyclohexanol CP- 47,497 C8 homologue). (g) Any schedule I controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise Regulation - Page 5 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes. Regulation - Page 6 of 7 Connecticut eRegulations System , Tracking Number PR2025-018 , Posted 9/18/2025 Statement of Purpose The purpose of this regulation is to designate new substances to the controlled substance list as required by Public Act 25-101, Section 4. This new law requires the Commissioner of Consumer Protection to designate the substances added to subsection (i) of that section as controlled substances and classify each such substance in the appropriate schedule. Since such substances currently have no medical use, pursuant to the Federal Drug Administration (FDA), and may not be prescribed or dispensed by a medical professional, the Department of Consumer Protection proposes this regulation to place the substances in schedule 1. However, if any of the substances are rescheduled by the FDA, this regulation contains an existing provision in subsection (g) to adopt the schedule determined by the FDA. Regulation - Page 7 of 7
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap